Baricitinib

Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Retrieved on: 
Wednesday, November 15, 2023
SUN, Feedback, Safety, Deucravacitinib, JAK, HUB, Patient satisfaction, Dermatology, AA, Baricitinib, Patient, Alopecia areata, Element, FDA, Benchmarking, Lilly, Hair loss, Launch, Upadacitinib, Communication, Physician, Horizon, Education, Pharmaceutical industry, Marketing, Pfizer

Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.

Key Points: 
  • Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.
  • Prescribers of both brands express high and comparable satisfaction levels, far surpassing the satisfaction rates associated with non-advanced systemic treatment options.
  • Recent data from Spherix's published studies highlight minimal differentiation among prescribers regarding the two JAK inhibitors.
  • Furthermore, barriers preventing increased use of either JAK inhibitor remain closely contested, with safety concerns topping the list for each asset.

Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata

Retrieved on: 
Tuesday, July 11, 2023
Pfizer, JAK, Atopic dermatitis, Rheumatoid arthritis, Eli Lilly, Dermatology, Alopecia areata, Patient, AD, FDA, News, Safety, Pharmaceutical industry, AA, Baricitinib

​Indeed, Dupixent’s AD user base and patient initiations displayed consecutive gains at a similar post-launch timing, while Olumiant’s may have already begun to plateau.

Key Points: 
  • ​Indeed, Dupixent’s AD user base and patient initiations displayed consecutive gains at a similar post-launch timing, while Olumiant’s may have already begun to plateau.
  • Litfulo is the second JAK inhibitor for AA, though it will be the first JAK3/TEC available in dermatology.
  • When comparing Olumiant and Litfulo at similar pre-launch time points, nearly half of dermatologists reported at least moderate familiarity with Olumiant for AA.
  • Coverage of Olumiant’s launch in AA will continue through December 2023, with planned coverage of Litfulo beginning once commercially available​.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, NLP, Medicines and Healthcare products Regulatory Agency, Drug discovery, Baricitinib, Euronext Amsterdam, IPF, CTA, AstraZeneca, CKD, Business analyst, Benevolence, Completeness, Google Knowledge Graph, MHRA, Chronic kidney disease, COVID-19, FDA, Idiopathic pulmonary fibrosis, Eli Lilly, BAI, Françoise Astorg Bollack, Natural language processing, Patent, IND, Medical device, Management, Pharmaceutical industry, Cryptocurrency, Sanofi

BenevolentAI (“BenevolentAI” or the “Company” or the “Group”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company” or the “Group”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, said:
    “With the world’s attention on AI applications that deliver real-world impact, our progress in 2022 strongly positions BenevolentAI to capitalise on this moment.
  • Our AI platform is proven to enhance drug discovery, as demonstrated by our growing pipeline and successful collaboration with AstraZeneca.
  • Net cash, cash equivalents and short-term deposits position of £130.2 million as of 31 December 2022 at the top end of market guidance (2021: £40.6m)
    Maintained cash runway to Q4 2024, despite inflationary headwinds

MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment

Retrieved on: 
Wednesday, February 22, 2023
Inflammation, FDA, Baricitinib, Eli Lilly and Company, Pfizer, FFA, AA, Dermatology, Alopecia areata, Hair loss, Pain, REACH, Patient, JAK, Pharmaceutical industry

NEWTON, Mass., Feb. 22, 2023 /PRNewswire/ -- Since the June 2022 approval of Eli Lilly's Olumiant (baricitinib), the AA market landscape has been dynamic with two more oral JAK inhibitors (e.g., Pfizer's ritlecitinib and SUN/Concert Pharmaceutical's deuruxolitinib) likely to be approved in the next year. In contrast, there is no FDA-approved treatment for FFA, a rare hair loss condition with a high clinical and psychosocial burden marked by frontal hairline recession and inflammation causing itching, pain, and burning.

Key Points: 
  • According to REACH Market Research , dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata (AA).
  • In contrast, there is no FDA-approved treatment for FFA, a rare hair loss condition with a high clinical and psychosocial burden marked by frontal hairline recession and inflammation causing itching, pain, and burning.
  • Currently, FFA patients are managed primarily with off-label:
    However, JAK inhibitor use is not widespread (
  • Physicians are eager for treatment options indicated specifically for FFA able to achieve complete response defined as stopping hair loss and inflammatory progression of the disease.

Aided by "Clean" FDA Label, US Dermatologists Report BMS' Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights

Retrieved on: 
Thursday, December 8, 2022
Pfizer, Benchmarking, GI, TYK2, Nephrology, Psoriasis, Protein, Patient, Amgen, Cancer, JAK, Thrombus, Gastroenterology, Death, MOA, Upadacitinib, Disease, FDA, Neurology, Overalls, BMS, Ophthalmology, Rheumatology, Safety, Education, Dermatology, AbbVie, Inflammation, Adalimumab, Baricitinib, Risk, Pharmaceutical industry, Apremilast, PSO

EXTON, Pa., Dec. 8, 2022 /PRNewswire/ -- On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective TKY2 inhibitor available in the US to treat the disease. In October 2022, Spherix began tracking the launch of Sotyktu as part of their Launch Dynamix™ series in which approximately 75 US dermatologists provide monthly perspectives on their use and perceptions of Sotyktu in PsO.

Key Points: 
  • Over one-third of dermatologists report already prescribing the drug to their PsO patients, and current and future initiations are highly positive.
  • There remains a subset of dermatologists that are hesitant of the safety profile, associating Sotyktu with the broader JAK class.
  • Spherix Global Insights is a leading provider of market intelligence and advisory services to the global life sciences industry.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

The European Medicines Agency's Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis - A Cause for Concern? Spherix Investigates

Retrieved on: 
Wednesday, December 7, 2022
Rheumatology, RA, Physician, Baricitinib, Nephrology, United Kingdom, Rheumatoid arthritis, HCP, Risk, European Medicines Agency, MACE, EMA, Patient, Cancer, JAK, Gastroenterology, PRAC, Upadacitinib, Neurology, Ophthalmology, Smoking, News, Dermatology, AbbVie, Eli Lilly and Company, Tofacitinib, Pharmaceutical industry, EU

EXTON, Pa., Dec. 7, 2022 /PRNewswire/ -- On October 28, 2022, the European Medicines Agency's (EMA) safety committee (PRAC) announced recommendations to minimize the risk of serious side effects when using JAK inhibitors to treat chronic inflammatory disorders. Spherix collected immediate reactions, opinions, and potential impacts of this news through their RealTime Dynamix™ research series, which surveyed approximately 271 rheumatologists across the EU5 countries (France, Germany, Italy, Spain, and the United Kingdom).

Key Points: 
  • Despite this, over half of respondents agreed they have concerns about the risk of MACE and malignancies when using any JAK inhibitor not just Xeljanz.
  • EU5 physicians expect the new guidelines to affect approximately two-fifths of their RA patients, regardless of whether they possess risk factors or not.
  • RealTime Dynamixis an independent study service by Spherix Global Insights that provides strategic guidance through quarterly or semiannual reports.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

Eli Lilly's Olumiant is Filling a Critical Gap for Severe Alopecia Areata Patients, According to Spherix Global Insights

Retrieved on: 
Thursday, November 17, 2022
Growth, AD, Neurology, Dermatology, Benchmarking, Eli Lilly, Nephrology, Physician, Safety, FDA, AA, Education, Research, JAK, Patient, Psoriasis, Upadacitinib, Ophthalmology, Atopic dermatitis, AbbVie, Gastroenterology, Alopecia areata, Ixekizumab, Lilly, Disease, Pharmaceutical industry, Baricitinib, Pfizer

EXTON, Pa., Nov. 17, 2022 /PRNewswire/ -- On June 13, 2022, Eli Lilly announced the FDA approval of Olumiant for severe alopecia areata (AA), making it the first systemic therapy available in the US to treat the disease. In July 2022, Spherix began tracking the launch of Olumiant as part of the Launch Dynamix™ series, in which approximately 75 US dermatologists provide perspectives on their use and perceptions of Olumiant in AA on a monthly basis.

Key Points: 
  • Despite this growth, the number of patients actually prescribed Olumiant suggests dermatologists are very much still in trial mode.
  • Dermatologists are often prescribing Olumiant to patients with severe disease, or 50-99% scalp hair loss, and often after multiple alternative treatment attempts.
  • Despite the vocalized desire amongst sampled dermatologists for increased education from the manufacturer, Olumiant is clearly filling a once-felt void of treatment.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

Dr. Brett King Joins BiologicsMD as Senior Scientific Advisor and Member of the Scientific Advisory Board

Retrieved on: 
Tuesday, October 18, 2022
Janus, Yale University, Female, Yale School of Medicine, Skin, Bone, Hospital, Woman, Infection, Degenerative disease, Membrane protein, Patient, Drug development, Eyebrow, Thrombosis, Hair, Hair loss, Research, Malignancy, Man, Massachusetts General Hospital, Mortality, Cancer, Vitiligo, Coronavirus Scientific Advisory Board (Turkey), University, Immune system, Alopecia areata, Doctor of Philosophy, MD, Spinal fusion, Atopic dermatitis, Board, CEO, Associate, Board of directors, Stanford University, Baricitinib, Scalp, JAK, Chronic kidney disease-mineral and bone disorder, Eyelash, Male, Management, Medical device, Pharmaceutical industry, Vaccine, Dermatology, HAVEN

NEW HAVEN, Conn., Oct. 18, 2022 /PRNewswire/ -- BiologicsMD, a preclinical therapeutic development company focused on highly-targeted treatments for hair loss and bone disorders, announced today the appointment of Brett King, MD, PhD, Associate Professor of Dermatology at Yale Medical School, as a Senior Scientific Advisor to the company's management team and Board of Directors.

Key Points: 
  • As the Senior Scientific Advisor, Dr. King will also serve as a member of BiologicsMD's Scientific Advisory Board.
  • Dr. Brett King has more than 10 years of clinical research and medical practice experience in the field of alopecia areata.
  • "Having Dr. King join BiologicsMD as our Senior Scientific Advisor is a testament to our progress to date," stated J. David Owens, CEO of BiologicsMD.
  • BiologicsMD is a therapeutic development company focused on developing targeted treatments of hair loss disorders, as well as severe bone disorders.

HAIR LOSS AWARENESS MONTH 2022

Retrieved on: 
Thursday, July 21, 2022
Janus, Patient, COVID-19, Adult, Multimedia, Hair, Transplant, Conditioners, Skin, Digital, Woman, DHT, Baricitinib, CNC, Dietary supplement, Head, FUE, Technology, Platelet-rich plasma, Cuban medical internationalism, Alopecia areata, DNA, Hair loss, Physician, PRP, Industry, JAK, Scalp, Saliva, Immune system, Pressure regulator, FDA, Formula, TED, Man, Time, View, Telogen effluvium, Artificial intelligence, BOCA, Forbes, Regenerative medicine, Cosmetics, Medical imaging, Pharmaceutical industry, Boost, Sandalore

BOCA RATON, Fla., July 21, 2022 /PRNewswire/ -- With topics such as Alopecia Areata (the impetus of the infamous Oscars Slap) and Covid Related Hair Shedding continuing to make headlines, hair loss remains a top-of-mind issue for the masses. The American Hair Loss Association estimates that at least 80 million men and women are currently suffering from hair loss across the country. August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology. Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr. Alan J. Bauman, and mastermind behind Biohacking Baldness, discusses the newest effective technology aimed at both preserving and restoring hair.

Key Points: 
  • The American Hair Loss Association estimates that at least 80 million men and women are currently suffering from hair loss across the country.
  • August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology.
  • TrichotestGenetic Hair Loss Testing uses state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis.
  • Based on a machine-learning algorithm, the HairMetrix system provides real-time analysis of hair density, hair caliber, and other metrics without the need for any hair trimming.

New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly's Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights

Retrieved on: 
Wednesday, June 22, 2022
Nephrology, Eli Lilly, FDA, Alopecia areata, Rheumatology, Safety, Dermatology, Gastroenterology, Adoption, JAK, US, Vitiligo, Disease, Physician, Clinical trial, Atopic dermatitis, Hidradenitis suppurativa, Patient, AA, Geography, Prurigo nodularis, Pharmaceutical industry, Baricitinib, EU

EXTON, Pa., June 22, 2022 /PRNewswire/ -- Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative interviews to assess the current and future treatment paradigm of alopecia areata (AA) patients. The firm also surveyed 100 US-based dermatologists in October 2021 on the same topic area, following up with ten qualitative interviews.

Key Points: 
  • The firm also surveyed 100 US-based dermatologists in October 2021 on the same topic area, following up with ten qualitative interviews.
  • Prior to the approval (and still in the EU), dermatologists relied primarily on topical corticosteroids, followed by intralesional corticosteroids.
  • Regardless of geography, adoption of Olumiant for the treatment of AA has the potential to be swift, post commercial availability.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.